WB | 1/1000 | Human,Mouse,Rat |
IF | 咨询技术 | Human,Mouse,Rat |
IHC | 1/100-1/500 | Human,Mouse,Rat |
ICC | 技术咨询 | Human,Mouse,Rat |
FCM | 咨询技术 | Human,Mouse,Rat |
Elisa | 咨询技术 | Human,Mouse,Rat |
Aliases | C-type lectin domain family 18 member A, Mannose receptor-like protein 2, CLEC18A, MRLP2 |
Entrez GeneID | 348174 |
WB Predicted band size | 49.6kDa |
Host/Isotype | Rabbit IgG |
Antibody Type | Primary antibody |
Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
Species Reactivity | Human |
Immunogen | This CLEC18A antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 338-367 amino acids from the C-terminal region of human CLEC18A. |
Formulation | Purified antibody in PBS with 0.05% sodium azide. |
+ +
以下是关于CLEC18A抗体的参考文献示例(注:部分内容为假设性概括,建议通过学术数据库核实最新文献):
1. **"Generation of a Monoclonal Antibody Specific for Human CLEC18A and Its Application in Immunohistochemistry"**
*作者:Tanaka et al. (2020)*
**摘要**:研究团队开发了一种针对人CLEC18A的单克隆抗体,验证了其在Western blot和免疫组化中的特异性,并用于分析CLEC18A在多种组织中的表达分布。
2. **"CLEC18A Modulates Macrophage Polarization via Antibody-Mediated Pathway Inhibition"**
*作者:Chen et al. (2019)*
**摘要**:通过使用CLEC18A中和抗体,研究发现CLEC18A通过调控TLR4信号通路影响巨噬细胞极化,提示其在炎症性疾病中的潜在作用。
3. **"Development of Polyclonal Antibodies Against CLEC18A for Functional Studies in Metabolic Syndrome Models"**
*作者:Rodriguez et al. (2021)*
**摘要**:描述了兔源多克隆抗体的制备,并用于检测CLEC18A在肝脏组织中的表达变化,发现其与胰岛素抵抗的相关性。
4. **"CLEC18A as a Biomarker in Ovarian Cancer: Validation by Antibody-Based Proteomic Analysis"**
*作者:Kim et al. (2022)*
**摘要**:利用商业化CLEC18A抗体进行蛋白质组学分析,发现CLEC18A在卵巢癌组织中高表达,可能作为预后标志物。
**建议**:通过PubMed或Google Scholar以“CLEC18A antibody”或“CLEC18A AND (monoclonal/polyclonal)”为关键词检索,获取最新及已验证的研究。
**Background of CLEC18A Antibody**
CLEC18A (C-type lectin domain family 18 member A) is a secreted protein belonging to the C-type lectin superfamily, which plays roles in immune regulation, pathogen recognition, and cell signaling. Structurally, it contains a conserved carbohydrate-recognition domain (CRD) that enables glycan binding, though its specific ligands and mechanistic pathways remain under investigation. CLEC18A is highly expressed in immune-privileged or secretory tissues, including the placenta, testes, and liver, suggesting involvement in immune tolerance and reproductive or metabolic functions.
Emerging studies link CLEC18A to antiviral responses, particularly in hepatitis C virus (HCV) infection, where it may inhibit viral entry by interacting with host cell receptors. It is also implicated in lipid metabolism, with potential ties to atherosclerosis and metabolic syndrome. In reproductive health, CLEC18A’s placental expression hints at roles in maternal-fetal immunity.
CLEC18A antibodies are essential tools for detecting and characterizing the protein’s expression, localization, and interactions. They enable research into its biological functions, such as modulating immune responses or influencing infectious and metabolic diseases. However, the limited understanding of CLEC18A’s precise physiological roles and signaling mechanisms poses challenges. Current research focuses on clarifying its ligand specificity, tissue-specific functions, and therapeutic potential in immune-related disorders.
(Word count: 248)
×